Colorectal cancers: Prognostic and predictive factors of response to treatment;Les cancers coliques: Facteurs pronostiques et prédictifs de la réponse au traitement

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 417-423

  Sablin, M P ^a   Italiano, A ^b   Spano, J P ^c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Colon cancer; Predictive factors; Prognostic factors

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB; PROTEIN P53; SMAD4 PROTEIN; THYMIDYLATE SYNTHASE;

CANCER STAGING; CHROMOSOME 18; CHROMOSOME 18Q; CHROMOSOME LOSS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; GENE MUTATION; HEREDITY; HUMAN; MICROSATELLITE INSTABILITY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 66349108206     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0781     Document Type: Review

References (52)

1. Hill C, Doyon F. La fréquence des cancers en France en 2002 et son évolution depuis 1968. Bull Cancer 2006 ; 93 : 7-11.
2. Hill C, Doyon F. La fréquence des cancers en France : mortalité en 2003, évolution depuis 1968 et cancers de l'enfant. Bull Cancer 2007 ; 94 : 7-13.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988 ; 319 : 525-532 (Pubitemid 18215829)
4. Meyerhardt JA, Mayer RJ. Drug therapy: systematic therapy for colorectal cancer. N Engl J Med 2005 ; 352 : 476-487 (Pubitemid 40175974)
5. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004 ; 37 : 66-75.
6. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging handbook. 6th ed. New York : Springer, 2002.
7. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988 ; 61 : 1018-1023
8. Compton CC. Surgical pathology of colorectal cancer. Humana press, 2002.
9. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007 ; 99 : 433-441 (Pubitemid 47073566)
10. McLeod HL, Murray GI. Tumor markers of prognosis in colorectal cancer. Br J Cancer 1999 ; 79 : 191-203. (Pubitemid 29002285)
11. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcome in node negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997 ; 185 : 55-59 (Pubitemid 27276742)
12. Filella X, Molina R, Piqué JM, Grau JJ, Garcia-Valdecasas JC, Biete A, et al. CEA as a prognostic factor in colorectal cancer. Anticancer Res 1994 ; 14 : 705-708 (Pubitemid 24172195)
13. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer. Cancer 2005 ; 104 : 2035-2047
14. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, Santini A, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998 ; 79 : 390-395 (Pubitemid 28359738)
15. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998 ; 16 : 427-433 (Pubitemid 28135583)
16. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994 ; 331 : 213-221 (Pubitemid 24226678)
17. Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, et al. Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: a study matched for T- and N- classification. Br J Cancer 2006 ; 95 : 1562-1567 (Pubitemid 44863360)
18. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998 ; 67 : 753-791
19. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and prometastatic factor in human cancer. Biochim Biophys Acta 2007 ; 1775 : 21-62. (Pubitemid 44881193)
20. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005 ; 11 : 2606-2611 (Pubitemid 40569460)
21. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of DPC4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 2000 ; 157 : 1105-1111
22. Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, et al. Immunohistochemical labeling for DPC4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000 ; 156 : 37-43. (Pubitemid 30644436)
23. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele Jr. G, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996 ; 335 : 1727-1732 (Pubitemid 26399347)
24. Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 1994 ; 19 : 525-531 (Pubitemid 24071327)
25. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000 ; 342 : 69-77. (Pubitemid 30036597)
26. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000 ; 408 : 307-310
27. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001 ; 1 : 233-240 (Pubitemid 33741898)
28. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003 ; 100 : 8424-8429 (Pubitemid 36842561)
29. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006 ; 17 : 842-847
30. Mollevi DG, Serrano T, Ginesta MM, Valls J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 2007 ; 28 : 1241-1246 (Pubitemid 47062683)
31. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001 ; 37 (Suppl 4) : S9-15. (Pubitemid 32938124)
32. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995 ; 1 : 19-31.
33. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005 ; 16 : 102-108 (Pubitemid 40124486)
34. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004 ; 52 : 893-901. (Pubitemid 38857154)
35. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001 ; 92 : 1331-1346 (Pubitemid 32861685)
36. Van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non-selected colon cancer cell lines. Clin Cancer Res 1999 ; 5 : 643-654 (Pubitemid 29131976)
37. Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002 ; 15 (20) : 2832-2843 (Pubitemid 34651512)
38. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 ; 349 : 247-257 (Pubitemid 36859476)
39. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001 ; 344 : 1196-1206 (Pubitemid 32319494)
40. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003 ; 9 : 2898-2903 (Pubitemid 36993247)
41. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 : 337-345 (Pubitemid 38944402)
42. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 ; 25 : 1658-1664 (Pubitemid 46797944)
43. Saltz LB, Meropol NJ, Loehrer Sr. PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004 ; 22 : 1201-1208 (Pubitemid 41079832)
44. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor. J Clin Oncol 2005 ; 23 : 1803-1810
45. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment incolorectal cancer: a cohort study. Lancet Oncol 2005 ; 6 : 279-286 (Pubitemid 40590264)
46. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of HER2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004 ; 17 : 895-904. (Pubitemid 38993773)
47. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006 ; 24 : 4914-4921 (Pubitemid 46630920)
48. Italiano A, Follana P, Caroli FX, Badetti JL, Benchimol D, Garnier G. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis do not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008 ; 15 (2) : 649-654 [Epub 2007 Nov 7].
49. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. K-ras mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 15 (66) : 3992-3995
50. Amado RG, Wolf M, Freeman D, Peeters M, Van Cutsem E, Siena S, et al. Analysis of K-ras mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. ECCO 14. (Abstract 7LB#).
51. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, et al. Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007 ; 25 : 3930-3935 (Pubitemid 47477270)
52. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and Kras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007 ; 25 : 3230-3237 (Pubitemid 47325606)